People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Pharma, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Halda Therapeutics, LLC | — | Pharma | Series D+ | $197.9M | $1.3B | 2024 |
| Lb Pharmaceuticals Inc | — | Pharmaceuticals | Series D+ | $141.4M | $1.5B | 2023 |
| Imbria Pharmaceuticals, Inc. | — | Biotechnology | Series C | $140.2M | $406.0M | 2025 |
Rebecca Luse at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rebecca Luse on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Tim Shannon | 1 | 9 |
| Robert Ruffolo | 1 | 8 |
| Chen Yu | 1 | 7 |
| Scott Phillips | 1 | 5 |
| Arjun Goyal | 1 | 5 |
| Nandita Shangari | 1 | 4 |
| Liam Ratcliffe | 1 | 4 |
| Zina Affas Besse | 1 | 4 |
| Rajul Jain | 1 | 3 |
| Ran Nussbaum | 1 | 3 |
| Marc Panoff | 1 | 2 |
| Joe Cabral | 1 | 2 |
| Rebecca Frey | 1 | 2 |
| Wei Zhao | 1 | 2 |
| Ken Horne | 1 | 2 |
| Charles Dunn | 1 | 2 |
| Piero Poli | 1 | 1 |
| Mark Panoff | 1 | 1 |
| Lauren Stipp | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.